Company profile
ALVOTECH
NASDAQ:ALVOBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SELARSDI | approved | — | 0 | — |
| SELARSDI | approved | — | 0 | — |
| SIMLANDI | approved | — | 0 | — |
| SIMLANDI | approved | — | 0 | — |
| ADALIMUMAB | phase3 | — | 59 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05632211 | phase1 | completed | 2022-12-16 | 2023-10-03 | Alvotech Swiss AG | A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants |
| NCT05126784 | phase1 | completed | 2022-06-29 | 2023-10-16 | Alvotech Swiss AG | AVT03 With Prolia in Healthy Male Subjects |
| NCT05876949 | phase1 | completed | 2023-07-21 | 2024-04-15 | Alvotech Swiss AG | AVT03 With Xgeva in Healthy Male Subjects |
| NCT05155293 | phase3 | completed | 2022-06-28 | 2023-11-17 | Alvotech Swiss AG | Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) |
| NCT07489131 | phase3 | recruiting | 2026-04-22 | 2027-07-01 | Alvotech Swiss AG | Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761343 | 2024-04-16 | BLA | ALVOTECH USA INC. | |||||
Loading… | ||||||||
| BLA 761299 | 2024-02-23 | BLA | ALVOTECH USA INC. | |||||
Loading… | ||||||||